The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin by Kasper, Bernd et al.
Mar. Drugs 2009, 7, 331-340; doi:10.3390/md7030331 
 
Marine Drugs  
ISSN 1660-3397 
www.mdpi.com/journal/marinedrugs 
Article 
The Use of Positron Emission Tomography in Soft Tissue 
Sarcoma Patients under Therapy with Trabectedin 
 
Bernd Kasper 
1,*, Thomas Schmitt 
1, Patrick Wuchter 
1, Antonia Dimitrakopoulou-Strauss 
2, 
Anthony D. Ho 
1 and Gerlinde Egerer 
1 
 
1  Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 
Heidelberg, Germany; E-Mails: Thomas.Schmitt@med.uni-heidelberg.de (T.S.); 
Patrick.Wuchter@med.uni-heidelberg.de (P.W.); Anthony.Ho@med.uni-heidelberg.de (A.H.); 
Gerlinde.Egerer@med.uni-heidelberg.de (G.E.) 
2  Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer 
Feld 280, D-69120 Heidelberg, Germany; E-Mail: ads@ads-lgs.de 
 
* Author to whom correspondence should be addressed; E-Mail: mail@berndkasper.de;  
Tel.: +49-6221-56-8008; Fax: +49-6221-56-6824 
 
Received: 23 June 2009; in revised form: 14 July 2009 / Accepted: 17 July 2009 /  
Published: 17 July 2009 
 
 
Abstract:  Background: We used 2-deoxy-2-[
18F] fluoro-D-glucose (FDG) positron 
emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or 
metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, 
Trabectedin, Yondelis
TM). Patients and Methods : The pilot study included nine patients 
with metastatic STS receiving a minimum of one cycle of treatment with trabectedin. 
Patients were examined using PET prior to onset of therapy and after completion of one or 
three cycles of trabectedin. Restaging according to Response Evaluation Criteria in Solid 
Tumours (RECIST) was performed in parallel using computed tomography (CT) and/or 
magnetic resonance imaging (MRI) and served for reference. Results: Clinical outcome of 
nine evaluable patients was as follows: one patient with partial remission (PR), three 
patients with stable disease (SD), and five patients with progressive disease (PD). A more 
than 40% decrease of the standardized uptake value (SUV) of sequential PET examination 
could be demonstrated for the responding patient (PR), whereas patients with SD or PD 
showed a stable SUV, but no increase in SUV. Conclusion: To our knowledge, this is the 
first small series of patients being treated with trabectedin and monitored using sequential 
PET imaging demonstrating SUV stabilization in nearly all monitored patients. 
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1. Introduction 
 
Soft tissue sarcomas (STS) are a heterogeneous group of connective tissue malignancies arising 
from tissue of mesenchymal origin. They constitute less than 1% of all adult malignancies. The   
five-year overall survival rate in patients with STS of all stages amounts to only 50–60% [1]; most 
patients die of metastatic disease, which becomes evident in 80% of the cases within two to three years 
after initial diagnosis [2]. Despite improvements in local tumour control rates, the treatment of patients 
with high risk STS remains challenging. For patients with no evidence of metastatic disease surgery is 
the primary treatment of choice. The high rate of distant disease recurrence suggests that undetectable 
metastatic disease is present in a significant percentage of patients with large, high grade STS at the 
time of surgery. Therefore an effective systemic treatment with chemotherapy is needed. Doxorubicin 
and ifosfamide are the most active single-agents in the therapy of STS with response rates above  
20% [3]. So far, the benefit of neither adjuvant chemotherapy [4] nor neoadjuvant chemotherapy has 
yet been finally clarified [5]. 
Therefore, it is important to identify patients who are likely to benefit from chemotherapy or other 
molecular targeted agents. Morphologic imaging modalities like CT and MRI can be used for the 
assessment of tumour localization, size, and infiltration of the surrounding tissue as well as presence of 
satellite metastases. However, it has not been well established whether a significant change in the 
tumour size is a meaningful tool of outcome of patients with STS. Standard radiographic response has 
not correlated consistently with histological response or with disease-free or overall survival [6–7]. 
Other methods to identify patients who are likely to benefit from chemotherapy or other agents would 
be useful. Therefore, PET with 
18F-FDG has found increasing use in oncology, because it allows 
functional imaging of viable tumour tissue [8]. However, not all tumours are PET avid, despite being 
viable. 
It was shown that FDG PET can visualize STS and detect local and distant recurrence of   
disease [9–10]. It was demonstrated that the SUV correlates well with the metabolic rate of FDG 
accumulation in tumour cells [11]. Hence, the SUV could function as an easily measurable surrogate 
of tumour viability during therapy. For other tumour entities, correlation between FDG accumulation 
after neoadjuvant chemotherapy and histological response as well as tumour response was shown, for 
example in breast cancer [12], oesophageal cancer [13], colorectal cancer [14], and gastrointestinal 
stromal tumours [15]. In a group of 46 patients with localized, intermediate/high grade, extremity STS, 
Schuetze et al. could demonstrate that changes of the SUV before and after neoadjuvant chemotherapy 
can be used to predict therapy outcome [16]. The multivariate analysis found a correlation between 
lack of response and increased risk of disease recurrence, metastases and death after appropriate local 
control of sarcoma. This study suggested that FDG PET can act as a non-invasive method in high risk 
extremity STS to predict patients who are less likely to benefit from doxorubicin-based   
chemotherapy [17]. Mar. Drugs 2009, 7 
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Ecteinascidin-743 (ET-743, Trabectedin, Yondelis
TM) is a tetrahydroisoquinoline alkaloid isolated 
from the Caribbean marine tunicate, Ecteinascadia turbinate . ET-743 is a DNA guanine-specific 
minor groove binding agent that blocks the cell cycle in the late S and G phase. Five phase II trials in 
Europe and the United States revealed a response rate of 10% in pre-treated and 18% in untreated 
patients with response duration of about ten months and a progression-free survival of 24% at 6 
months and 9% at 12 months [18–19]. In particular, anti-tumour activity has been demonstrated in 
leiomyosarcomas and liposarcomas. ET-743 seems to be especially active in the myxoid variant of 
liposarcomas associated with translocations of t(12;16)(q13;p11) or t(12;12)(q13;q12); among 15 
retrospectively reviewed cases eight objective responses were found [20]. There is only one phase I 
study monitoring patients being treated with trabectedin with FDG PET. Although there were no 
objective responses to therapy, clear evidence of anti-tumour activity was observed in a patient with 
epithelioid mesothelioma as confirmed by PET [21]. 
The purpose of the present study, which is the first covering this topic, was to analyse and discuss 
semi-quantitative FDG PET measurements in STS patients treated with trabectedin. 
 
2. Patients and Methods 
 
Patients  
 
The pilot study includes nine patients with STS. Patients’ characteristics including gender, age, 
histologies and grading according to the Federation Nationale des Centres de Lutte Contre le Cancer 
(FNCLCC) system [22], tumour and metastatic sites as well as line of treatment are summarized in 
Table 1. All patients were referred to our outpatient service with a diagnosis of a STS confirmed by 
histology obtained from surgical specimens. Tumour specimens were classified according to the 
FNCLCC system. Patients were treated with trabectedin in the Department of Internal Medicine V, 
University of Heidelberg between September 2008 and June 2009. The research was carried out 
according to the principles set out in the Declaration of Helsinki in 1964 and all subsequent revisions. 
 
Ecteinascidin-743  
 
Nine patients with metastatic disease received trabectedin in a dose of 1.5 mg/m
2/day 1 as a 24 hour 
continuous infusion, repetition day 22 for at least one cycle. Altogether, we performed 18 cycles of 
therapy; treatment was continued until disease progression. One patient received trabectedin in a 
reduced dose of 1.3 mg/m
2 because of liver metastases with elevated liver parameters. In spite of 
CTCAE grade I/II fatigue, nausea and neutropenia, no major (grade III and IV) toxicities occurred. 
 
Imaging studies  
 
Patients were examined using FDG PET prior to onset of therapy and after completion of one to 
three cycles of trabectedin. Conventional imaging of the same target lesion using CT and/or MRI was 
performed in parallel to determine the response according to RECIST criteria. This data served as 
reference to evaluate the response determined with FDG PET. Dynamic PET studies were performed Mar. Drugs 2009, 7 
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after intravenous injection of 300–370 MBq FDG for 60 min. A dedicated PET system (ECAT 
EXACT HR plus, Siemens, Erlangen, Germany) was used for patient studies as described before [23]. 
The last images (55–60 minutes post-injection) were used for semi-quantitative analysis. PET cross-
sections were reconstructed with an image matrix of 256 × 256 using an iterative reconstruction 
program. Images were scatter- and attenuation-corrected. Volumes of interest (VOI) were placed over 
the lesion. To acquire information about the tumour viability, the hyper-metabolic areas of the tumours 
were evaluated and hypo-metabolic areas that correlate to necrotic tissue were excluded. The SUV in 
the tumour was calculated according to the following equation: SUV = tissue concentration (MBq/g) / 
[injected dose (MBq)/body weight (g)]. The SUV reflected the average SUV value provided by the 
quantification software in a VOI. This value is more robust than the maximum SUV (SUVmax), 
because it is less influenced by the parameters used for the image reconstruction as well as by potential 
artefacts. The analysis of the PET images was performed together by two nuclear medicine physicians 
using the software package Pmod (PMod Technologies Ltd., Adlisvil, Switzerland) [24]. 
 
Statistical analysis  
 
Due to the small number of patients we performed a descriptive analysis of the data. Progression-
free survival was defined as the time interval from the date of therapy induction until the tumour 
recurred or the patient died of sarcoma-related causes. 
 
Table 1. Patients’ characteristics (n = 9). 
Gender 
 Female    6 
 Male  3 
Age 
  Median (years)  52 [range: 26–73] 
Histology 
 Synovial  sarcoma  2 
 Leiomyosarcoma  7 
Grading 
 II  2 
 III  7 
Tumour site at initial diagnosis 
 None  1 
 Extremities  3 
 Trunk  5 
Metastatic sites 
 Lung  8 
 Liver  3 
 Lymph  nodes  3 
 Soft  tissue  2 
Line of Treatment 
 2
nd line    4 
 3
rd line or more  5 Mar. Drugs 2009, 7 
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3. Results and Discussion 
 
Clinical response based on RECIST criteria  
 
First CT and/or MRI scan was performed in all patients prior to onset of therapy with trabectedin. 
Restaging was performed using CT and/or MRI after one (n = 2) or three (n = 4) cycles of trabectedin. 
The remission status was evaluated according to RECIST criteria based on the tumour shrinkage in the 
CT and/or MRI scan. Clinical outcome according to RECIST criteria was as follows: one patient with 
PR, three patients with SD, and five patients with PD. The median progression-free survival from the 
date of therapy induction for all patients was 2.8 months [range: 0–7] with a median follow-up of 3.8 
months [range: 1–7]. 
 
Clinical response based on PET imaging  
 
The median average SUV prior to onset of targeted therapy with trabectedin was 7.6   
[range: 1.2–19.3] in comparison to 5.8 [range: 1.4–20.1] after treatment. The median SUVmax was 14.1 
[range: 4.5–28.7] prior to therapy with trabectedin in comparison to 16.1 [range: 6.1–32.4] following 
treatment. We compared the average SUV values with the clinical response data according to RECIST 
criteria using conventional MRI and/or CT. One patient achieving PR showed a significant decrease of 
the SUV (6.7 > 3.5, decrease of 48%) and the SUVmax (13.5 > 6.1, decrease of 54%) indicating tumour 
response to treatment; the patient further continued treatment with trabectedin. In the literature, a cut-
off value of 40% reduction from baseline has been chosen to differentiate responders [25]. Three 
patients with SD after one (n = 2) or three (n = 1) cycles of trabectedin demonstrated no major change 
in SUV indicating tumour stabilization; all patients continued treatment with trabectedin. Two patients 
with PD under treatment with trabectedin also showed stabilization of the SUV; nevertheless, 
treatment with trabectedin was stopped due to RECIST criteria. Two patients received only one cycle 
of trabectedin and died within one month after start of therapy due to PD and therefore were not 
evaluable regarding sequential PET examinations. One patient received two cycles of trabectedin and 
showed documented PD; no PET follow-up examination was performed due to refusal of the patient. 
Hence, a significant decrease (> 40%) of the SUV of the sequential PET examinations could be 
demonstrated for one responding patient (PR), whereas patients with SD or even PD showed 
stabilization of the SUV. There was no patient in this series demonstrating an increase of the SUV. 
The PET examinations seem to confirm what we know about the characteristics of trabectedin; it has a 
remarkable ability to slow the growth and stabilize the tumour, which is reflected by our results 
regarding SUV values. Moreover, we could show that sequential PET imaging with a second PET scan 
after treatment with trabectedin may be used to determine whether STS patients will benefit from 
therapy or not. 
 
Example  
 
In order to demonstrate that PET imaging may provide additional information compared to 
conventional MRI and/or CT, we describe a case from one of our patients (Figure 1): A 62 year old Mar. Drugs 2009, 7 
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female with a leiomyosarcoma, grade III, of the vena cava with lung and liver metastases. The FDG 
PET prior therapy with trabectedin showed an average SUV of 6.7 and a SUVmax of 13.5 (upper left 
image). After three cycles of treatment with trabectedin, the FDG PET demonstrated a decrease of the 
average SUV to 3.5 and of the SUVmax to 6.1 (upper right image) and a decrease of the FDG uptake in 
all other evaluable lesions. The corresponding conventional CT documented PR according to RECIST 
(lower left and right images). This case underlines the common finding that the structure of the tumour 
may change reflected by a decline of the average and the maximum SUV caused by a change of the 
vessel density, blood circulation or necrosis even though the tumour size itself remains rather stable. 
 
Figure 1. Case of a 62 year old female with a leiomyosarcoma, grade III, of the vena cava 
with lung and liver metastases. FDG PET showed a decrease of the average SUV from 6.7 
and of the SUVmax from 13.5 (upper left image ) to 3.5 and 6.1 (upper right image ), 
respectively, as well as a decline of the FDG uptake in all evaluable lesions (mSUV PET 
images, colour-scales are directly comparable (0–10 SUV)). As an example, the 
corresponding CT scan showed the reduction in size of one reference lesion in the lung 
demonstrating a PR according to RECIST criteria (lower left and right images ). 
Additionally, liver metastases demonstrated a partial remission (not shown). 
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Discussion  
 
There have been different implications for the use of PET in STS. It has been studied to predict the 
malignant potential and grade of tumours, to stage the malignant disease, to monitor tumour response 
to chemotherapy, to predict clinical benefit from chemotherapy, and to detect tumour recurrence after 
primary therapy [26]. However, most of the studies have analysed only a small number of patients and 
have used different imaging protocols and evaluation procedures. Therefore, comparison of the 
different studies and analysis seems to be difficult. Nevertheless, there is no doubt that FDG PET is 
useful in the clinical management of bone and soft tissue sarcoma patients [17]. 
During the last decade change in tumour size to cytotoxic treatment has been the parameter to 
predict the therapeutic benefit for the patients. However, changes in tumour size in soft tissue 
sarcomas measured with CT and/or MRI were not correlated consistently with patients’ outcomes. 
Especially for gastrointestinal stromal tumours (GIST), this finding has already been well documented. 
A study of FDG PET in imatinib treated GIST showed that patients with normalization of tumour SUV 
within the first month of treatment have significantly longer time to progression of disease and better 
overall survival than those patients with increased FDG accumulation [27]. FDG PET appears to be 
more useful than CT/MRI imaging in GIST to predict response to therapy. Moreover, there is even 
doubt if RECIST criteria adequately describe the remission status to chemotherapy or to other targeted 
agents. 
To our knowledge, the present paper describes the first small series of heavily pre-treated patients 
under therapy with trabectedin being monitored using sequential PET imaging. The purpose of the 
study was to describe certain PET characteristics of trabectedin and to identify patients who are likely 
to benefit from treatment. In our own study with high grade STS patients receiving neoadjuvant 
chemotherapy, we could demonstrate that FDG PET may be used as a tool to predict patients’ therapy 
outcome while differentiating between responders and non-responders after a limited drug   
exposure [28]. There is only one phase I study using FDG PET to monitor patients receiving 
trabectedin. Although there were no objective responses in that study, clear evidence of anti-tumour 
activity was observed in one patient with epithelioid mesothelioma as confirmed by a 40% reduction in 
FDG uptake after two cycles [21]. In our population of heavily pre-treated patients, we demonstrated a 
more than 40% decline of the SUV in our sequential PET examination for one responding patient 
(PR), whereas all patients with SD or even PD showed stabilization of the SUV. There was no patient 
demonstrating a SUV increase. However, the present data could not add any additional information to 
conventional imaging methods using CT and/or MRI. PET scan should be most useful in patients with 
SD; however, there was no change in SUV in this group of patients. Of course, these limitations of the 
study could be due to the low number of evaluated patients or to the short follow-up time of the 
present data. 
 
4. Conclusions 
 
Taken together, FDG PET will certainly play an increasingly important prognostic and predictive 
role in the management of sarcomas. It could be used to assess the aggressiveness of the tumour in 
order to make early clinical decisions whether treatment is useful for the patient or not [28]. Our Mar. Drugs 2009, 7 
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present data suggest that the characteristics of trabectedin are reflected by PET examinations. 
Trabectedin shows a remarkable ability to slow the growth and stabilize the tumour indicated by 
stabilization or even decrease of the SUV values. Furthermore, PET imaging may be used in order to 
predict response to therapy early in the course of treatment for cytotoxic chemotherapy as well as 
targeted agents such as kinase inhibitors or trabectedin. However, more data have to be evaluated. 
FDG PET imaging may complement radiological tomography and histological grading, thus 
improving the assessment of STS and implying an influence on therapeutic decisions in the future. 
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